Geographic Atrophy Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The market size of Geographic Atrophy is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)

[Nevada, United States] - DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Geographic Atrophy, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Geographic Atrophy Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Geographic Atrophy Market Report:
The Geographic Atrophy market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: Alexion Pharmaceuticals, Inc. announced a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatment arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.
In September, 2024: Annexon, Inc. announced that the purpose of their study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
In August, 2024: Genentech, Inc.announced that a study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
In August, 2024: Annexon, Inc. announced that a study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate.
In August, 2024: Regeneron Pharmaceuticals announced that a study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have geographic atrophy (GA) caused by age-related macular degeneration (AMD).
Among the 7MM, the US accounted for the highest prevalent cases of geographic atrophy in 2023 while Japan accounted for the least number of prevalent cases
According to the estimates, in Japan, it is observed that age-specific cases of geographic atrophy were most prevalent in the 8 + years age group, accounting for over 40% of total cases in 2023.
Launching multiple stage Geographic Atrophy pipeline products is expected to revolutionize market dynamics, further propelling market growth.
Key Geographic Atrophy Companies are as follows: Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
Key Geographic Atrophy Therapies are as follow: IZERVAY, SYFOVRE, Tinlarebant, Gildeuretinol, Danicopan BI 771716, JNJ-81201887, Prednisone, ONL1204 Ophthalmic solution, RO7303359, CLG561, LFG316

Dive into our detailed Geographic Atrophy market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Geographic Atrophy Overview:
Geographic Atrophy (GA) is a progressive and severe form of age-related macular degeneration (AMD) that leads to the gradual loss of retinal pigment epithelium (RPE) cells and photoreceptors. This condition significantly impairs vision and can result in blindness. Here's an in-depth look at Geographic Atrophy, including its pathophysiology, diagnosis, treatment options, and ongoing research.

Geographic Atrophy Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Geographic Atrophy Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Geographic Atrophy companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Geographic Atrophy Therapies and Key Companies:
IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio
SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals
Tinlarebant (LBS-008): Belite Bio
Gildeuretinol (ALK-001): Alkeus Pharmaceuticals
Danicopan: Alexion Pharmaceuticals, Inc.
BI 771716: Boehringer Ingelheim
JNJ-81201887, Prednisone: Janssen Research & Development, LLC
ONL1204 Ophthalmic solution: ONL Therapeutics
RO7303359: Hoffmann-La Roche
CLG561, LFG316: Alcon Research

Geographic Atrophy Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Geographic Atrophy.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Geographic Atrophy Epidemiology Segmentation:
The Geographic Atrophy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Geographic Atrophy Total Prevalence
Geographic Atrophy Prevalent Cases by severity
Geographic Atrophy Gender-specific Prevalence
Geographic Atrophy Diagnosed Cases of Episodic and Chronic

Geographic Atrophy Market Drivers:
Rising Prevalence of Age-Related Macular Degeneration (AMD)
Advancements in Research and Development
Growing Investment in Ophthalmology
Unmet Medical Need

Geographic Atrophy Market Barriers:
High Development Costs
Patient Compliance and Access
Market Penetration and Adoption

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Geographic Atrophy Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Geographic Atrophy Companies: Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
Key Geographic Atrophy Therapies: IZERVAY, SYFOVRE, Tinlarebant, Gildeuretinol, Danicopan BI 771716, JNJ-81201887, Prednisone, ONL1204 Ophthalmic solution, RO7303359, CLG561, LFG316
Geographic Atrophy Therapeutic Assessment: Current marketed and emerging therapies
Geographic Atrophy Market Dynamics: Geographic Atrophy Market drivers and Geographic Atrophy barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Geographic Atrophy Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Geographic Atrophy market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Executive Summary of Geographic Atrophy
4 Key Events
5 Geographic Atrophy Epidemiology and Market Forecast Methodology
6 Geographic Atrophy Market Overview at a Glance
7 Disease Background and Overview
8 Geographic Atrophy Epidemiology and Patient Population
9 Geographic Atrophy Patient Journey
10 Marketed Geographic Atrophy Drugs
11 Emerging Geographic Atrophy Drugs
12 Geographic Atrophy Market Analysis
13 Geographic Atrophy Unmet Needs
14 Geographic Atrophy SWOT Analysis
15 Geographic Atrophy KOL Views
16 Geographic Atrophy Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.